SS Innovations has conducted Indonesia's first robotic cardiac surgery using SSi Mantra, its surgical robotic system.
The surgical procedures including a bilateral internal mammary artery coronary artery bypass graft (IMA CABG), and an atrial septal defect (ASD) repair and beating-heart totally endoscopic coronary artery bypass (TECAB), were carried out at Harapan Kita National Cardiac Hospital in Jakarta.
The company’s founder, chairman and CEO Dr Sudhir Srivastava led the first beating-heart TECAB in the country, with assistance from his team and the hospital staff.
The company and the hospital’s surgical team conducted seven to eight additional robotic-assisted surgeries over the subsequent days after the initial TECAB procedure.
SS Innovations founder, chairman and CEO Dr Sudhir Srivastava said: “We are proud to partner with Harapan Kita National Cardiac Hospital to bring the most technologically advanced and cost-effective solutions to cardiac surgery to Indonesia.
“Reaching this milestone with SSi Mantra is a testament to our vision of transforming surgical practices, enhancing access, and driving the global adoption of cost-effective robotic surgery.
“This collaboration addresses the critical need for safe, timely, and affordable cardiac care while offering patients less invasive options and an improved quality of life.”
A modular multi-arm system, SSi Mantra is claimed to be equipped with advanced technology features, including an ergonomic Surgeon Command Centre and a large 3D 4K monitor.
The modular arms are claimed to ensure collision-free surgery and support more than 40 varieties of robotic endo-surgical instruments suitable for several specialities, including cardiac surgery.
Given the system’s ergonomic design and user-friendly interface, the learning curve for surgeons is shorter, stated the company.
Having been clinically validated in India across more than 80 surgical procedures, the SSi Mantra received approval from the Indonesian Ministry of Health in July.
The company is currently pursuing regulatory approvals in the US and the European Union, with expectations of securing them in the H2 2025.
